Soft Tissue Sarcoma Program
The Soft Tissue Sarcoma Program at Texas Children’s Cancer Center is one of the largest programs in the nation, providing care to children and adolescents with newly suspected or confirmed soft tissue sarcomas. Our multidisciplinary team of experts specializes in the care of a variety of common as well as rare pediatric sarcomas, including rhabdomyosarcoma, synovial sarcoma, liposarcoma, fibrosarcoma, clear cell sarcoma, alveolar soft part sarcoma, undifferentiated sarcoma, BCOR-CCNB3 sarcomas (BCS), CIC-DUX sarcomas, and others. We provide a comprehensive personalized, high-quality, family-centered approach to treating our patients that includes a multi-disciplinary team of physicians and other health care providers.
Our multidisciplinary team is comprised of nationally and internationally recognized experts in pediatric oncology, surgical oncology, orthopedic surgery, otolaryngology (ENT surgery), radiation oncology, radiology, pathology and cancer genetics. Our team also includes dedicated pediatric nurses, social workers, child life specialists, psychologists, and pharmacists.
Treatment and Evaluation
Treatments for soft tissue sarcoma may include one or more of the following: surgery, radiation therapy, chemotherapy, or targeted therapies, including immunotherapy. Our team works together to develop an individualized treatment approach based on a comprehensive analysis of the genetic and genomics of the tumor and other characteristics of the tumor including its location and size.
Texas Children’s Hospital has state-of-the-art anatomic pathology, cytogenetics, and molecular pathology laboratories which conduct comprehensive testing and provide timely and accurate results. Our Precision Oncology Consultation Service offers advanced genomic testing to discover genetic changes specific to individual tumors which may aid in treatment decisions.
We also offer very specialized surgical techniques such as HIPEC (hyperthermic intraperitoneal chemotherapy) as well as state-of-the-art radiotherapy, including proton therapy, when indicated.
Texas Children’s Cancer Center is a member of the Children’s Oncology Group (COG) and participates in many clinical trials for the treatment of newly diagnosed and relapsed cancers, including sarcomas. Our patients have access to many novel, early phase clinical trials of promising new drugs or immunotherapies through our Developmental Therapeutics Program as well as The Russell and Glenda Gordy Center for Innovative Therapies.
Sarcoma research at Texas Children’s spans from epidemiologic and basic science laboratory-based research (investigating causes of tumor development and metastasis) to translational research (aimed at discovering new therapies to inform future clinical trials), to the development of institutional and multi-center clinical trials. Our research teams have expertise in drug development, as well as in cellular and immune therapy approaches.